Updated molecular epidemiology of carbapenem-non-susceptible Escherichia coli in Taiwan: first identification of KPC-2 or NDM-1-producing E. coli in Taiwan

BMC Infectious Diseases
Ling MaYin-Ching Chuang

Abstract

The global spread and increasing incidence of carbapenem-resistant Enterobacteriaceae have resulted in treatment and public health concerns. Here, we present an investigation of the molecular mechanisms and clonality of carbapenem-non-susceptible Escherichia coli (CnSEC) based on a nationwide survey in Taiwan. We collected 32 and 43 carbapenem-non-susceptible E. coli isolates in 2010 and 2012, respectively. The genes encoding cabapenemases and plasmidic AmpC-type and extended-spectrum β-lactamases (EBSLs) were analyzed by polymerase chain reaction (PCR). The major porin channels OmpF and OmpC were evaluated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Molecular typing was performed with pulsed-field gel electrophoresis (PFGE) and multi-locus sequence typing (MLST). The resistance rates of CnSEC isolates to cefazolin, cefotaxime, cefoxitin, ceftazidime, and ertapenem were all 100%, and most (94.7%) isolates were CMY producers. The main mechanism of CnSEC in Taiwan is via plasmidic AmpC β-lactamase CMY-2 and DHA-1 in combination with the loss of OmpC/F. In 2010, one isolate was confirmed to harbor blaIMP-8; a KPC-2 producer and an NDM-1 producer were detected in 2012. No isolate had VIM- or OXA-carbape...Continue Reading

References

Dec 6, 2001·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·E M D'AgataJ G Kusters
Jun 27, 2002·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·P Nordmann, L Poirel
Jan 27, 2004·Antimicrobial Agents and Chemotherapy·M AlvarezG A Jacoby
Aug 7, 2004·Journal of Clinical Microbiology·Laurent PoirelPatrice Nordmann
May 13, 2006·Molecular Microbiology·Thierry WirthMark Achtman
Jun 23, 2006·FEMS Microbiology Letters·Patrick FreireCecília M Arraiano
Aug 31, 2006·Antimicrobial Agents and Chemotherapy·Shiri Navon-VeneziaYehuda Carmeli
Dec 6, 2006·Antimicrobial Agents and Chemotherapy·Ze-Qing WeiLan-Juan Li
Mar 8, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Simona BratuJohn Quale
Jun 8, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Yohei Doi, Yoshichika Arakawa
Jul 17, 2007·Clinical Microbiology Reviews·Anne Marie Queenan, Karen Bush
Oct 22, 2008·Antimicrobial Agents and Chemotherapy·Ling MaUNKNOWN Taiwan Surveillance of Antimicrobial Resistance Project
Dec 26, 2008·JAMA : the Journal of the American Medical Association·Mitchell J Schwaber, Yehuda Carmeli
Mar 28, 2009·The Lancet Infectious Diseases·Patrice NordmannThierry Naas
Jan 12, 2010·International Journal of Antimicrobial Agents·Gisele Peirano, Johann D D Pitout
Mar 17, 2010·Antimicrobial Agents and Chemotherapy·Moran G GorenYehuda Carmeli
Sep 21, 2010·Diagnostic Microbiology and Infectious Disease·Ana Paula D'Alincourt Carvalho-AssefElizabeth Andrade Marques
Nov 18, 2010·The Journal of Antimicrobial Chemotherapy·Benjamin A RogersDavid L Paterson
Mar 12, 2011·The Journal of Antimicrobial Chemotherapy·Kuei-Pin ChungPo-Ren Hsueh
Jun 15, 2011·The Journal of Antimicrobial Chemotherapy·S MushtaqN Woodford
Jul 20, 2011·Antimicrobial Agents and Chemotherapy·Thierry NaasPatrice Nordmann
Jul 20, 2011·Antimicrobial Agents and Chemotherapy·Dearbháile MorrisMartin Cormican
Oct 18, 2011·Diagnostic Microbiology and Infectious Disease·Béatrice BerçotPatrice Nordmann
Jan 10, 2012·International Journal of Antimicrobial Agents·Angeliki MavroidiEfthymia Petinaki
Feb 1, 2012·Antimicrobial Agents and Chemotherapy·Tsai-Ling LauderdaleShan-Chwen Chang
Apr 12, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Young Ah KimYohei Doi
Jun 19, 2012·The Korean Journal of Internal Medicine·David M Livermore
Mar 19, 2013·Frontiers in Microbiology·Gopi Patel, Robert A Bonomo

❮ Previous
Next ❯

Citations

Dec 3, 2014·International Journal of Antimicrobial Agents·Hung-Jen TangL Kristopher Siu
Jul 8, 2015·World Journal of Microbiology & Biotechnology·Guofeng XuXiuying Zhang
Oct 21, 2014·Expert Opinion on Pharmacotherapy·Ying Ching TanKwang Sik Kim
Apr 29, 2014·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·L W Riley
May 3, 2016·Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi·Hung-Jen TangYin-Ching Chuang
Sep 29, 2015·PloS One·Ling MaPo-Liang Lu
Mar 21, 2015·PloS One·Jann-Tay WangShan-Chwen Chang
Aug 19, 2016·Scientific Reports·Chih-Cheng LaiHung-Jen Tang
Mar 26, 2015·Expert Review of Anti-infective Therapy·Hanna E Sidjabat, David L Paterson
Feb 1, 2020·Annual Review of Food Science and Technology·Lee W Riley
Jun 14, 2019·Clinical Microbiology Reviews·Amee R MangesJohann D D Pitout
Feb 23, 2019·Journal of Clinical Medicine·Chih-Wei ChenChih-Cheng Lai
Dec 13, 2018·Frontiers in Microbiology·Shio-Shin JeanPo-Ren Hsueh
Jul 19, 2020·Antibiotics·Andressa Liberal SantosLilian Carla Carneiro

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR
electrophoresis

Software Mentioned

BioNumerics
Vitek2

Related Concepts

Related Feeds

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.